234 related articles for article (PubMed ID: 3132618)
1. [Sphingolipid storage diseases of the central nervous system: bases of biochemical and clinical heterogeneity].
Sandhoff K; Quintern L
Naturwissenschaften; 1988 Mar; 75(3):123-31. PubMed ID: 3132618
[TBL] [Abstract][Full Text] [Related]
2. Sphingolipids and neuronal degeneration in lysosomal storage disorders.
Grassi S; Chiricozzi E; Mauri L; Sonnino S; Prinetti A
J Neurochem; 2019 Mar; 148(5):600-611. PubMed ID: 29959861
[TBL] [Abstract][Full Text] [Related]
3. Neuronal sphingolipidoses: Membrane lipids and sphingolipid activator proteins regulate lysosomal sphingolipid catabolism.
Sandhoff K
Biochimie; 2016 Nov; 130():146-151. PubMed ID: 27157270
[TBL] [Abstract][Full Text] [Related]
4. Characterization of
Sellin J; Schulze H; Paradis M; Gosejacob D; Papan C; Shevchenko A; Psathaki OE; Paululat A; Thielisch M; Sandhoff K; Hoch M
Dis Model Mech; 2017 Jun; 10(6):737-750. PubMed ID: 28389479
[TBL] [Abstract][Full Text] [Related]
5. The expanding boundaries of sphingolipid lysosomal storage diseases; insights from Niemann-Pick disease type C.
Platt FM
Biochem Soc Trans; 2023 Oct; 51(5):1777-1787. PubMed ID: 37844193
[TBL] [Abstract][Full Text] [Related]
6. Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell.
Sandhoff K; Kolter T; Van Echten-Deckert G
Ann N Y Acad Sci; 1998 Jun; 845():139-51. PubMed ID: 9668348
[TBL] [Abstract][Full Text] [Related]
7. Genetic defects in the sphingolipid degradation pathway and their effects on microglia in neurodegenerative disease.
Allende ML; Zhu H; Kono M; Hoachlander-Hobby LE; Huso VL; Proia RL
Cell Signal; 2021 Feb; 78():109879. PubMed ID: 33296739
[TBL] [Abstract][Full Text] [Related]
8. My journey into the world of sphingolipids and sphingolipidoses.
Sandhoff K
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(10):554-82. PubMed ID: 23229750
[TBL] [Abstract][Full Text] [Related]
9. Pathology and current treatment of neurodegenerative sphingolipidoses.
Eckhardt M
Neuromolecular Med; 2010 Dec; 12(4):362-82. PubMed ID: 20730629
[TBL] [Abstract][Full Text] [Related]
10. A view on sphingolipids and disease.
Kolter T
Chem Phys Lipids; 2011 Sep; 164(6):590-606. PubMed ID: 21570958
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and novel treatments for sphingolipidoses.
Arenz C
Future Med Chem; 2017 Sep; 9(14):1687-1700. PubMed ID: 28857617
[TBL] [Abstract][Full Text] [Related]
12. The genetics of sphingolipid hydrolases and sphingolipid storage diseases.
Schuchman EH; Simonaro CM
Handb Exp Pharmacol; 2013; (215):3-32. PubMed ID: 23579447
[TBL] [Abstract][Full Text] [Related]
13. How membrane dysfunction influences neuronal survival pathways in sphingolipid storage disorders.
Sural-Fehr T; Bongarzone ER
J Neurosci Res; 2016 Nov; 94(11):1042-8. PubMed ID: 27638590
[TBL] [Abstract][Full Text] [Related]
14. Molecular facets of sphingolipids: mediators of diseases.
Ozbayraktar FB; Ulgen KO
Biotechnol J; 2009 Jul; 4(7):1028-41. PubMed ID: 19579220
[TBL] [Abstract][Full Text] [Related]
15. Sphingolipids and their role in health and disease in the central nervous system.
Leal AF; Suarez DA; Echeverri-Peña OY; Albarracín SL; Alméciga-Díaz CJ; Espejo-Mojica ÁJ
Adv Biol Regul; 2022 Aug; 85():100900. PubMed ID: 35870382
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy of Sphingolipid Metabolic Disorders.
Shaimardanova AA; Solovyeva VV; Issa SS; Rizvanov AA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835039
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of an activator protein for sphingolipid hydrolysis in liver and brain samples from patients with lysosomal storage diseases.
Inui K; Wenger DA
J Clin Invest; 1983 Nov; 72(5):1622-8. PubMed ID: 6415115
[TBL] [Abstract][Full Text] [Related]
18. Storage diseases: new insights into sphingolipid functions.
Sillence DJ; Platt FM
Trends Cell Biol; 2003 Apr; 13(4):195-203. PubMed ID: 12667757
[TBL] [Abstract][Full Text] [Related]
19. The role of brain innate immune response in lysosomal storage disorders: fundamental process or evolutionary side effect?
Vitner EB
FEBS Lett; 2020 Nov; 594(22):3619-3631. PubMed ID: 33131047
[TBL] [Abstract][Full Text] [Related]
20. Sphingolipids and cell signalling.
Fredman P
J Inherit Metab Dis; 1998 Aug; 21(5):472-80. PubMed ID: 9728328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
